Literature DB >> 21316047

In vivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates.

Mary B Zelinski1, Mark K Murphy, Maralee S Lawson, Andrea Jurisicova, K Y Francis Pau, Natalia P Toscano, Darla S Jacob, John K Fanton, Robert F Casper, Stephen D Dertinger, Jonathan L Tilly.   

Abstract

OBJECTIVE: To determine whether sphingosine-1-phosphate (S1P), or the S1P mimetic FTY720 shields ovaries of adult female rhesus monkeys from damage caused by 15 Gy of targeted radiotherapy, allowing for the retention of long-term fertility, and to evaluate whether S1P protects human ovarian tissue (xenografted into mice) from radiation-induced damage.
DESIGN: Research animal study.
SETTING: Research laboratory and teaching hospital. PATIENT(S): Adult female rhesus macaques (8-14 years of age; n = 21) and two women (24 and 27 years of age) undergoing gynecologic surgery for benign reasons, after informed consent and approval. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Ovarian histologic analysis, ovarian reserve measurements, and fertility in mating trials. RESULT(S): Rapid ovarian failure was induced in female macaques by ovarian application of 15 Gy of radiation. Females given S1P or FTY720 by direct intraovarian cannulation for 1 week before ovarian irradiation rapidly resumed menstrual cycles because of maintenance of follicles, with greater beneficial effects achieved using FTY720. Monkeys given the S1P mimetic before ovarian irradiation also became pregnant in mating trials. Offspring conceived and delivered by radioprotected females developed normally and showed no evidence of genomic instability, as measured by micronucleus frequency in reticulocytes. Adult human ovarian cortical tissue xenografted into mice also exhibited a reduction in radiation-induced primordial oocyte depletion when preexposed to S1P. CONCLUSION(S): S1P and its analogs hold clinical promise as therapeutic agents to preserve ovarian function and fertility in female cancer patients exposed to cytotoxic treatments.
Copyright © 2011 American Society for Reproductive Medicine. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21316047      PMCID: PMC3063448          DOI: 10.1016/j.fertnstert.2011.01.012

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  30 in total

1.  Molecular requirements for doxorubicin-mediated death in murine oocytes.

Authors:  A Jurisicova; H-J Lee; S G D'Estaing; J Tilly; G I Perez
Journal:  Cell Death Differ       Date:  2006-01-27       Impact factor: 15.828

2.  Defects in regulation of apoptosis in caspase-2-deficient mice.

Authors:  L Bergeron; G I Perez; G Macdonald; L Shi; Y Sun; A Jurisicova; S Varmuza; K E Latham; J A Flaws; J C Salter; H Hara; M A Moskowitz; E Li; A Greenberg; J L Tilly; J Yuan
Journal:  Genes Dev       Date:  1998-05-01       Impact factor: 11.361

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction.

Authors:  G I Perez; C M Knudson; L Leykin; S J Korsmeyer; J L Tilly
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

5.  In vitro grown human ovarian follicles from cancer patients support oocyte growth.

Authors:  Min Xu; Susan L Barrett; Erin West-Farrell; Laxmi A Kondapalli; Sarah E Kiesewetter; Lonnie D Shea; Teresa K Woodruff
Journal:  Hum Reprod       Date:  2009-07-13       Impact factor: 6.918

Review 6.  Ovarian tissue cryopreservation--new opportunity to preserve fertility in female cancer patients.

Authors:  M Huser; I Crha; R Hudecek; P Ventruba; J Zakova; L Smardova; Z Kral
Journal:  Eur J Gynaecol Oncol       Date:  2007       Impact factor: 0.196

7.  Does sphingosine-1-phosphate have a protective effect on cyclophosphamide- and irradiation-induced ovarian damage in the rat model?

Authors:  Hakan Kaya; Raziye Desdicioglu; Mekin Sezik; Engin Ulukaya; Okan Ozkaya; Arzu Yilmaztepe; Meral Demirci
Journal:  Fertil Steril       Date:  2007-05-22       Impact factor: 7.329

8.  The radiosensitivity of the human oocyte.

Authors:  W H B Wallace; A B Thomson; T W Kelsey
Journal:  Hum Reprod       Date:  2003-01       Impact factor: 6.918

9.  Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment.

Authors:  S M Borman; K M Schwinof; C Niemeyer; K Chwalisz; R L Stouffer; M B Zelinski-Wooten
Journal:  Hum Reprod       Date:  2003-01       Impact factor: 6.918

10.  FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.

Authors:  Kunitomo Adachi; Kenji Chiba
Journal:  Perspect Medicin Chem       Date:  2007-09-06
View more
  37 in total

Review 1.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

2.  Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies.

Authors:  So-Youn Kim; Devi M Nair; Megan Romero; Vanida A Serna; Anthony J Koleske; Teresa K Woodruff; Takeshi Kurita
Journal:  Cell Death Differ       Date:  2018-07-09       Impact factor: 15.828

3.  Oxidative damage of DNA induced by X-irradiation decreases the uterine endometrial receptivity which involves mitochondrial and lysosomal dysfunction.

Authors:  Wei Gao; Jin-Xiao Liang; Shuai Liu; Chang Liu; Xiao-Fang Liu; Xiao-Qi Wang; Qiu Yan
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 4.  Challenges and Potential for Ovarian Preservation with SERMs.

Authors:  Alison Y Ting; Brian K Petroff
Journal:  Biol Reprod       Date:  2015-03-25       Impact factor: 4.285

Review 5.  Combating radiation therapy-induced damage to the ovarian environment.

Authors:  Francesca E Duncan; Bruce F Kimler; Shawn M Briley
Journal:  Future Oncol       Date:  2016-04-27       Impact factor: 3.404

6.  Subcutaneous ovarian tissue transplantation in nonhuman primates: duration of endocrine function and normalcy of subsequent offspring as demonstrated by reproductive competence, oocyte production, and telomere length.

Authors:  David M Lee; Carrie M Thomas; Fuhua Xu; Richard R Yeoman; Jing Xu; Richard L Stouffer; Don P Wolf; Mary B Zelinski
Journal:  J Assist Reprod Genet       Date:  2017-09-23       Impact factor: 3.412

7.  Diminished Utilization of in Vitro Fertilization Following Ovarian Transposition in Cervical Cancer Patients.

Authors:  Sana M Salih; Samet Albayrak; Songwon Seo; Sarah L Stewart; Kristen Bradley; David M Kushner
Journal:  J Reprod Med       Date:  2015 Jul-Aug       Impact factor: 0.142

Review 8.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

9.  Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy.

Authors:  Malgorzata E Skaznik-Wikiel; Megan M McGuire; Meena Sukhwani; Julia Donohue; Tianjiao Chu; Thomas C Krivak; Aleksandar Rajkovic; Kyle E Orwig
Journal:  Fertil Steril       Date:  2013-02-26       Impact factor: 7.329

10.  Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network.

Authors:  S-Y Kim; M H Cordeiro; V A Serna; K Ebbert; L M Butler; S Sinha; A A Mills; T K Woodruff; T Kurita
Journal:  Cell Death Differ       Date:  2013-04-19       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.